 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...216217218219220221222223224225226...235236» |
- ||||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial, Metastases: MATEO: Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer (clinicaltrials.gov) - Apr 28, 2014
P2, N=400, Not yet recruiting, Sponsor: AIO-Studien-gGmbH
- |||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
Enrollment open: STRATEGIC-1: Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 28, 2014
P3, N=474, Recruiting, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Not yet recruiting --> Recruiting
- ||| E7820 / Eisai
Enrollment closed, Metastases: Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer (clinicaltrials.gov) - Apr 28, 2014
P1/2, N=95, Active, not recruiting, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Cyramza (ramucirumab) / Eli Lilly, icrucumab (IMC-18F1) / Eli Lilly
Trial primary completion date, Combination therapy, Metastases: A Study of Ramucirumab or Icrucumab in Colorectal Cancer (clinicaltrials.gov) - Apr 27, 2014
P2, N=157, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2013 --> Dec 2013
- || Cyramza (ramucirumab) / Eli Lilly, icrucumab (IMC-18F1) / Eli Lilly
Trial completion date, Combination therapy, Metastases: A Study of Ramucirumab or Icrucumab in Colorectal Cancer (clinicaltrials.gov) - Apr 27, 2014
P2, N=157, Completed, Sponsor: Eli Lilly and Company
Trial primary completion date: Nov 2013 --> Dec 2013 Trial completion date: Nov 2014 --> Dec 2013
- |||| Cyramza (ramucirumab) / Eli Lilly, icrucumab (IMC-18F1) / Eli Lilly
Trial completion, Combination therapy, Metastases: A Study of Ramucirumab or Icrucumab in Colorectal Cancer (clinicaltrials.gov) - Apr 27, 2014
P2, N=157, Completed, Sponsor: Eli Lilly and Company
Trial completion date: Nov 2014 --> Dec 2013 Active, not recruiting --> Completed
- ||| Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment closed, Combination therapy, Metastases: A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan (clinicaltrials.gov) - Apr 27, 2014
P2, N=60, Active, not recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| prexasertib (ACR-368) / Acrivon Therap
New P1 trial, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Apr 24, 2014
P1, N=70, Not yet recruiting, Sponsor: Eli Lilly and Company
- Farydak (panobinostat) / Secura Bio
Trial suspension, Metastases: Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy (clinicaltrials.gov) - Apr 23, 2014
P1, N=50, Suspended, Sponsor: University of Southern California
Recruiting --> Active, not recruiting Recruiting --> Suspended
- Trial initiation date, Surgery: GCC 1324: Borderline Pancreas Study: FOLFIRINOX +SBRT (clinicaltrials.gov) - Apr 21, 2014
P0, N=20, Recruiting, Sponsor: University of Maryland
Recruiting --> Suspended Initiation date: Jan 2014 --> Mar 2014
- New P2 trial, Metastases: BCC-RAD-13: Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer (clinicaltrials.gov) - Apr 21, 2014
P2, N=28, Not yet recruiting, Sponsor: James Graham Brown Cancer Center
- Enrollment open, Surgery: GCC 1324: Borderline Pancreas Study: FOLFIRINOX +SBRT (clinicaltrials.gov) - Apr 21, 2014
P0, N=20, Recruiting, Sponsor: University of Maryland
Initiation date: Jan 2014 --> Mar 2014 Not yet recruiting --> Recruiting
- || Caprelsa (vandetanib) / Sanofi
Trial completion date, Combination therapy: A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer (clinicaltrials.gov) - Apr 16, 2014
P2, N=109, Active, not recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Trial completion date: Mar 2014 --> Mar 2015
- leucovorin calcium / Generic mfg.
Enrollment closed: Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study (clinicaltrials.gov) - Apr 14, 2014
P=N/A, N=10, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Mar 2014 --> Mar 2015 Recruiting --> Active, not recruiting
- | Avastin (bevacizumab) / Roche, dulanermin (AMG 951) / Amgen, Roche
Trial completion, Combination therapy, Metastases: A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 13, 2014
P1, N=23, Completed, Sponsor: Genentech
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | bortezomib / Generic mfg., thioguanine / Generic mfg.
New P3 trial: AALL1231: Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Apr 10, 2014
P3, N=1400, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment open: BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial (clinicaltrials.gov) - Apr 9, 2014
P2, N=25, Recruiting, Sponsor: howard safran
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Vectibix (panitumumab) / Amgen
Trial initiation date: PanaMa: Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 7, 2014
P2, N=280, Not yet recruiting, Sponsor: AIO-Studien-gGmbH
Not yet recruiting --> Recruiting Initiation date: Dec 2013 --> Apr 2014
- | New P1/2 trial, Metastases: NabucCO: Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 7, 2014
P1/2, N=114, Recruiting, Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica
- | Folotyn (pralatrexate) / Aurobindo
New P2 trial, Combination therapy: Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies (clinicaltrials.gov) - Apr 6, 2014
P2, N=20, Not yet recruiting, Sponsor: Spectrum Pharmaceuticals, Inc
- ||| Avastin (bevacizumab) / Roche
Biomarker, Enrollment closed, Metastases: MAVERICC: Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Apr 6, 2014
P2, N=377, Active, not recruiting, Sponsor: Genentech
Initiation date: Dec 2013 --> Apr 2014 Recruiting --> Active, not recruiting
- || Alymsys (bevacizumab-maly) - Amneal, Pharmaceutical Libbs, Grupo Insud, Nichi / Iko, Stada
Trial initiation date: Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN (clinicaltrials.gov) - Apr 3, 2014
P1, N=100, Not yet recruiting, Sponsor: mAbxience S.A
Recruiting --> Active, not recruiting Initiation date: Apr 2014 --> Jul 2014
- Enrollment open, Metastases: NabucCO: Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 3, 2014
P1/2, N=114, Recruiting, Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica
Initiation date: Apr 2014 --> Jul 2014 Not yet recruiting --> Recruiting
- Enrollment change, Metastases: Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer (clinicaltrials.gov) - Apr 2, 2014
P2, N=61, Recruiting, Sponsor: Pancreatic Cancer Research Team
Not yet recruiting --> Recruiting N=30 --> 61
- | floxuridine / Generic mfg.
New P2 trial: A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis (clinicaltrials.gov) - Apr 1, 2014
P2, N=71, Recruiting, Sponsor: Yuhong Li
- | Blincyto (blinatumomab) / Astellas, Amgen
New P3 trial: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 31, 2014
P3, N=438, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | New P2 trial: Gemcitabine plus nab-paclitaxel versus folfirinox in patients with potentially resectable pancreatic carcinoma. Tratamiento con gemcitabina mas nabpaclitaxel frente a folfirinox en pacientes con c (EUDRACT) - Mar 31, 2014
P2, N=56, Ongoing, Sponsor: FUNDACION HOSPITAL DE MADRID
- | Hepacid (pegargiminase) / Polaris Pharma
New P1 trial, Metastases: Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 31, 2014
P1, N=22, Not yet recruiting, Sponsor: Polaris Group
- Mekinist (trametinib) / Novartis, BeiGene
Enrollment open, Surgery, Metastases: SWOG-S1310: Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery (clinicaltrials.gov) - Mar 31, 2014
P2, N=89, Recruiting, Sponsor: National Cancer Institute (NCI)
N=30 --> 61 Not yet recruiting --> Recruiting
- | New P2 trial, Surgery: ESPAC-5F: European Study Group for Pancreatic Cancer - Trial 5F (EUDRACT) - Mar 30, 2014
P2, N=100, Ongoing, Sponsor: University of Liverpool`Royal Liverpool and Broardgreen University Hospitals Trust
- ||| Avastin (bevacizumab) / Roche
Enrollment closed, Combination therapy, Metastases: A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 30, 2014
P2, N=77, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | oxaliplatin / Generic mfg., cisplatin / Generic mfg., gemcitabine / Generic mfg.
Trial initiation date, Metastases: ABC06: Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers (clinicaltrials.gov) - Mar 28, 2014
P3, N=162, Recruiting, Sponsor: Christie Hospital NHS Foundation Trust
Recruiting --> Active, not recruiting Initiation date: Nov 2013 --> Feb 2014
- | oxaliplatin / Generic mfg., cisplatin / Generic mfg., gemcitabine / Generic mfg.
Enrollment open, Metastases: ABC06: Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers (clinicaltrials.gov) - Mar 28, 2014
P3, N=162, Recruiting, Sponsor: Christie Hospital NHS Foundation Trust
Initiation date: Nov 2013 --> Feb 2014 Not yet recruiting --> Recruiting
- ||| ensituximab (NEO-102) / ImmunityBio
Enrollment change, Metastases: QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer (clinicaltrials.gov) - Mar 27, 2014
P1/2, N=90, Recruiting, Sponsor: Precision Biologics, Inc
Not yet recruiting --> Recruiting N=34 --> 90
- |||| Vectibix (panitumumab) / Amgen
Trial completion: STEPP: Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy (clinicaltrials.gov) - Mar 27, 2014
P2, N=95, Completed, Sponsor: Amgen
N=34 --> 90 Active, not recruiting --> Completed
- New P2 trial: SINTART2: Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients (clinicaltrials.gov) - Mar 26, 2014
P2, N=25, Recruiting, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- New P2 trial, Surgery: SINTART 1: Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients (clinicaltrials.gov) - Mar 26, 2014
P2, N=40, Recruiting, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment closed, Combination therapy, Metastases: A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies (clinicaltrials.gov) - Mar 26, 2014
P1, N=20, Active, not recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Vectibix (panitumumab) / Amgen
Enrollment change: Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques (clinicaltrials.gov) - Mar 25, 2014
P2, N=80, Recruiting, Sponsor: Spanish Cooperative Group for Digestive Tumour Therapy (TTD)
Recruiting --> Active, not recruiting N=50 --> 80
- Campath (alemtuzumab) / Sanofi
Enrollment change: Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 19, 2014
P1/2, N=302, Completed, Sponsor: National Cancer Institute (NCI)
N=50 --> 80 N=71 --> 302
- peripheral blood stem cell transplantation / National Cancer Institute
Clinical: Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 18, 2014
P2, N=85, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=71 --> 302 Recruiting --> Active, not recruiting
- | thioguanine / Generic mfg., nelarabine / Generic mfg.
Enrollment change: AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Mar 17, 2014
P3, N=1900, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=1580 --> 1900
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial, Metastases: Study of S-1 Plus LV for Advanced Gastric Cancer (clinicaltrials.gov) - Mar 16, 2014
P2, N=39, Completed, Sponsor: Sun Yat-sen University
- | tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Enrollment closed, Combination therapy, Metastases: Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach (clinicaltrials.gov) - Mar 16, 2014
P1/2, N=50, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
N=1580 --> 1900 Recruiting --> Active, not recruiting
- || New P3 trial, Metastases: Perioperative FOLFIRI VS Adjuvant FOLFIRI in Resectable Advanced CRC Failed to Oxaliplatin (clinicaltrials.gov) - Mar 12, 2014
P3, N=360, Recruiting, Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
- Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
Enrollment open: CCRe-IV: Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases (clinicaltrials.gov) - Mar 12, 2014
P4, N=336, Recruiting, Sponsor: Hospital Universitari de Bellvitge
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., sorafenib / Generic mfg.
Enrollment open, Combination therapy, Metastases: Sorafenib + mFOLFOX for Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 12, 2014
P2, N=40, Recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Suspended --> Recruiting
- |||| gedatolisib (PF-05212384) / Celcuity
Enrollment open, Metastases: A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 11, 2014
P1/2, N=180, Recruiting, Sponsor: Pfizer
Suspended --> Recruiting Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly
Trial termination, Combination therapy, Metastases: A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis (clinicaltrials.gov) - Mar 6, 2014
P2, N=8, Terminated, Sponsor: Austrian Breast & Colorectal Cancer Study Group
Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.
- ||| simtuzumab (GS 6624) / Gilead
Enrollment closed, Metastases: Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma (clinicaltrials.gov) - Mar 5, 2014
P2, N=265, Active, not recruiting, Sponsor: Gilead Sciences
ABCSG guaranteed completed treatment period for ethical reasons. Recruiting --> Active, not recruiting